Loading
The trial that showed a gentler CAR-T design could treat adult ALL with a fraction of the severe side effects.
FELIX, trial NCT04404660 sponsored by Autolus and published in the New England Journal of Medicine in 2024, showed that a gentler CAR-T design, obecabtagene autoleucel, could treat adult relapsed or refractory B-cell acute lymphoblastic leukaemia with a fraction of the severe side effects of earlier products. Of 153 enrolled, 127 were infused; the overall remission rate was 77 percent with complete remission in 55 percent, severe cytokine release syndrome occurred in under three percent, and about forty percent were event-free at two years, most without transplant, leading to FDA approval on 8 November 2024 without a REMS programme. OnCo links it to acute lymphoblastic leukaemia, CAR-T, CD19 as a target and obecabtagene autoleucel, and the UCL predecessor ALLCAR19 showed the same profile. Whether the fast-off-rate design generalises to other CAR-T targets is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares Relapsed and refractory acute lymphoblastic leukaemia in children, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares CD19, Acute lymphoblastic leukaemia.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.